Unformatted text preview: to marketing through doctors (by informing them of the benefits and potential adverse side effects of their drugs)? 5. Did the Federal Drug Administration do a good job in monitoring the safety of Vioxx? Should the FDA have been more aggressive in pushing Merck to do more research and clinical trials regarding the safety of Vioxx following the results of the Naproxen study? Should the FDA have insisted on stronger warning labels? Why or why not? 6. Did Merck act appropriately in recalling Vioxx and ceasing all efforts to market Vioxx in September 2004? Should it have recalled the drug sooner? Why or why not?...
View Full Document
This note was uploaded on 07/15/2011 for the course BUS A 10001 taught by Professor All during the Spring '11 term at Shaheed Zulfiqar Ali Bhutto Institute of Science and Technology.
- Spring '11